Gilead Sciences filings document material events, operating results, governance matters and capital-structure disclosures for a Delaware biopharmaceutical company whose common stock trades as GILD on the Nasdaq Global Select Market. Form 8-K reports furnish quarterly and annual financial results, including GAAP and non-GAAP measures and reconciliations, and disclose completed acquisition activity affecting oncology pipeline assets.
Proxy and annual meeting filings record director elections, auditor ratification and shareholder voting outcomes. Other current reports cover executive and governance changes, Regulation FD disclosures, material agreements, and formal exhibits tied to Gilead’s virology and oncology business, including clinical or regulatory disclosure categories when they are part of the company’s public reporting.
Gilead Sciences insider Deborah Telman has filed a Form 144 notice to sell up to 29,215 shares of the company’s common stock on NASDAQ. The shares, with an aggregate market value of $3,771,948.65, are to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services. The issuer reports 1,240,679,623 common shares outstanding.
The stock to be sold comes from a stock option exercise of 26,215 shares on 01/22/2026 paid in cash and 3,000 restricted stock units granted on 07/25/2023. The filing also lists prior Rule 10b5-1 sales for Deborah Telman over the past three months, including transactions on 11/12/2025, 12/15/2025, and 01/15/2026 with disclosed gross proceeds for each sale.
Gilead Sciences director Jeffrey Bluestone exercised non-qualified stock options for 5,000 shares of common stock at $67.4500 per share on January 20, 2026, then sold 5,000 shares at $123.5000 per share the same day under a Rule 10b5-1 trading plan adopted on February 13, 2025. After these transactions, he holds 8,920 shares of Gilead common stock directly.
A holder filed a notice to sell 5,000 shares of the issuer’s common stock through Morgan Stanley Smith Barney, with an aggregate market value of $617,500 on NASDAQ.
The 5,000 shares are to be sold after being acquired the same day via a stock option exercise paid in cash. The issuer has 1,240,679,623 common shares outstanding. During the prior three months, the same seller, identified as Jeffrey Bluestone of Foster City, California, sold 5,000 common shares for gross proceeds of $625,400.
Gilead Sciences’ Chief Financial Officer Andrew D. Dickinson reported a small, pre-planned stock sale. On January 15, 2026, he sold 3,000 shares of Gilead common stock at a price of $124.31 per share. After this transaction, he continued to beneficially own 150,503 shares of the company’s common stock in direct ownership.
The sale was executed under a Rule 10b5-1 trading plan that was adopted on August 29, 2024, meaning the trade was scheduled in advance under a preset plan rather than being decided at the time of sale.
Gilead Sciences Chief Commercial Officer Johanna Mercier reported a sale of company stock in an insider transaction. On January 15, 2026, she sold 3,000 shares of Gilead Sciences common stock at a price of $124.31 per share, reported under transaction code "S" for a sale. After this transaction, she beneficially owned 103,221 shares of Gilead common stock in direct ownership.
The filing notes that this transaction was carried out under a Rule 10b5-1 trading plan, which was adopted on February 20, 2025. Such plans allow insiders to pre-arrange trades according to preset instructions, providing a structured way to sell shares over time.
Johanna Mercier has filed a Form 144 notice to sell 3,000 shares of common stock through Morgan Stanley Smith Barney on or about 01/15/2026 on the NASDAQ market. The planned sale has an aggregate market value of $372,930.00, and the issuer has 1,240,679,623 shares outstanding. The shares to be sold come from restricted stock and performance share awards acquired from the issuer in early 2024.
Over the past three months, Johanna Mercier has already sold 3,000 and 28,000 shares of common stock in separate transactions, with gross proceeds of $366,000.00 and $3,524,173.10, respectively. By signing the notice, the seller represents that they are not aware of any undisclosed material adverse information about the issuer’s current or prospective operations.
An insider has filed a Rule 144 notice to sell 3,000 shares of common stock of the issuer through Morgan Stanley Smith Barney LLC, with an aggregate market value of $372,930.00. The filing notes that there were 1,240,679,623 shares outstanding of this class, providing context for the size of the planned sale.
The shares to be sold were acquired on 01/24/2023 as performance shares from the issuer, with 3,000 securities acquired and deemed fully paid as of that date. The notice indicates an approximate sale date of 01/15/2026 on the NASDAQ exchange.
In the past three months, the person for whose account the securities are to be sold, Andrew Dickinson, has already sold 3,000 common shares on 12/15/2025 for gross proceeds of $366,000.00 and 2,500 common shares on 11/17/2025 for gross proceeds of $313,075.00. By signing, the seller represents that they do not know of undisclosed material adverse information about the issuer’s operations.
Gilead Sciences disclosed that its Chief Financial Officer, Andrew D. Dickinson, sold 3,000 shares of the company’s common stock on December 15, 2025 at a price of $122 per share. Following this sale, he beneficially owns 153,503 shares, held directly. The transaction was made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.
Gilead Sciences, Inc. reported an insider stock sale by its Chief Commercial Officer, Johanna Mercier. On 12/15/2025, Mercier sold 3,000 shares of Gilead common stock at $122 per share in a sale transaction coded "S".
After this sale, she beneficially owns 106,221 shares directly. The report notes that the transaction was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on February 20, 2025, which allows executives to schedule trades in advance.
Gilead Sciences CEO Daniel P. O'Day reported insider stock activity involving restricted stock units linked to Gilead Sciences, Inc. common stock. On 12/10/2025, 10,426 restricted stock units were converted into 10,426 shares of common stock, increasing his directly held shares before a related disposition.
On the same date, 4,931 shares of common stock were disposed of at a price of $ 121.34 per share. After these transactions, O'Day directly owned 576,698 shares of Gilead common stock and 88,070 restricted stock units. Each restricted stock unit represents the right to receive one share, and the units follow a four-year vesting schedule in which 25% vest on the first anniversary of the grant date and the remaining balance vests 6.25% quarterly until fully vested.